<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db12466 DrugCentral: favipiravir Synonymous :fapilavir | favilavir | favipiravir 
Drug Sentece Context Table 1. Analysis of context sentence of favipiravir gene in 46 abstracts.   pmid  sentence      32147628  Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far.">

  
  <link rel="alternate" hreflang="en-us" href="/drugpanel/favipiravir/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/drugpanel/favipiravir/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="/drugpanel/favipiravir/info/">
  <meta property="og:title" content="FAVIPIRAVIR | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db12466 DrugCentral: favipiravir Synonymous :fapilavir | favilavir | favipiravir 
Drug Sentece Context Table 1. Analysis of context sentence of favipiravir gene in 46 abstracts.   pmid  sentence      32147628  Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."><meta property="og:image" content="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>FAVIPIRAVIR | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">FAVIPIRAVIR</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db12466' target='_blank'>db12466</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=favipiravir" target="_blank">favipiravir</a> <br>
Synonymous :fapilavir | favilavir | favipiravir
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>favipiravir</em> gene in 46 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32147628" target="_blank">32147628</a>
</td>
<td style="text-align:center;">
Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32243270" target="_blank">32243270</a>
</td>
<td style="text-align:center;">
This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32246834" target="_blank">32246834</a>
</td>
<td style="text-align:center;">
Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. […] Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. […] We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32251767" target="_blank">32251767</a>
</td>
<td style="text-align:center;">
Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32256547" target="_blank">32256547</a>
</td>
<td style="text-align:center;">
We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). […] Se identificaron 24 ensayos clínicos relacionados con más de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. […] Foram identificados 24 ensaios clínicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32277367" target="_blank">32277367</a>
</td>
<td style="text-align:center;">
Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32284326" target="_blank">32284326</a>
</td>
<td style="text-align:center;">
In this regard, the triphosphate forms of 2’-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32290293" target="_blank">32290293</a>
</td>
<td style="text-align:center;">
The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including <i>favipiravir</i>, a broad-spectrum antiviral drug that interferes with the viral replication, and <i>hydroxychloroquine</i>, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32293834" target="_blank">32293834</a>
</td>
<td style="text-align:center;">
The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32297571" target="_blank">32297571</a>
</td>
<td style="text-align:center;">
Inaddition, remdesivir, which has been previously administered to Ebola virus patients, has alsoproven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy-chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies)were also recently recorded as having anti-SARS-CoV-2 effects.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32307245" target="_blank">32307245</a>
</td>
<td style="text-align:center;">
The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32329520" target="_blank">32329520</a>
</td>
<td style="text-align:center;">
Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32336586" target="_blank">32336586</a>
</td>
<td style="text-align:center;">
There are currently no therapeutic drugs available that are directly active against SARS-CoV-2; however, several antivirals (remdesivir, favipiravir) and antimalarials (chloroquine, hydroxychloroquine) have emerged as potential therapies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32338164" target="_blank">32338164</a>
</td>
<td style="text-align:center;">
The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32346491" target="_blank">32346491</a>
</td>
<td style="text-align:center;">
Herein, we examine the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32360480" target="_blank">32360480</a>
</td>
<td style="text-align:center;">
Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32372695" target="_blank">32372695</a>
</td>
<td style="text-align:center;">
Similarly, other investigational drugs such as favipiravir and lopinavir/ritonavir can prolong QT interval and cause Torsade de Pointes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32392072" target="_blank">32392072</a>
</td>
<td style="text-align:center;">
Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32394467" target="_blank">32394467</a>
</td>
<td style="text-align:center;">
Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32395418" target="_blank">32395418</a>
</td>
<td style="text-align:center;">
These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32397911" target="_blank">32397911</a>
</td>
<td style="text-align:center;">
In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32399094" target="_blank">32399094</a>
</td>
<td style="text-align:center;">
SARS-CoV-2 Mpro was docked with all statins, while antiviral and antiretroviral drugs - favipiravir, nelfinavir, and lopinavir - were used as standards for comparison. […] The binding energies obtained from the docking of 6LU7 with native ligand favipiravir, nelfinavir, lopinavir, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin, and atorvastatin were -6.8, -5.8, -7.9, -7.9, -7.0, -7.7, -6.6, -8.2, -7.4, -7.7, and -6.8 kcal/mol, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405421" target="_blank">32405421</a>
</td>
<td style="text-align:center;">
Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19. […] We aim to review existing favipiravir safety evidence, which is vital to informing the potential future use of favipiravir in COVID-19. […] All studies assessing the use of favipiravir in humans by 27 March 2020 were considered for inclusion. […] Twenty-nine studies were identified as potential sources of evidence of the clinical safety of favipiravir. […] The proportions of grade 1-4 AEs on favipiravir was 28.2% <i>vs</i> 28.4% (<i>P</i> = n.s.) in the comparison arms. […] The proportion of discontinuations due to AEs on favipiravir was 1.1% <i>vs</i> 1.2% (<i>P</i> = n.s.) in the comparison arms. […] There were significantly fewer gastrointestinal AEs occurring on favipiravir <i>vs</i> comparators [8.7% <i>vs</i> 11.5%; <i>P</i> = 0.003]. […] Favipiravir showed significantly more uric acid elevations than comparators [5.8% <i>vs</i> 1.3%; <i>P</i>&lt;0.0001]. […] Favipiravir demonstrates a favourable safety profile regarding total and serious AEs. […] Favipiravir may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment. […] Given the limitations of the evidence and unresolved safety concerns, caution is warranted in the widespread use of favipiravir against pandemic COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405423" target="_blank">32405423</a>
</td>
<td style="text-align:center;">
Minimum estimated costs of production were US $0.93/day for remdesivir, $1.45/day for favipiravir, $0.08/day for hydroxychloroquine, $0.02/day for chloroquine, $0.10/day for azithromycin, $0.28/day for lopinavir/ritonavir, $0.39/day for sofosbuvir/daclatasvir and $1.09/day for pirfenidone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32425246" target="_blank">32425246</a>
</td>
<td style="text-align:center;">
The only FDA approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon and colchicine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32448818" target="_blank">32448818</a>
</td>
<td style="text-align:center;">
The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32473756" target="_blank">32473756</a>
</td>
<td style="text-align:center;">
We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. […] Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. […] Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. […] NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. […] The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32475019" target="_blank">32475019</a>
</td>
<td style="text-align:center;">
The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32486229" target="_blank">32486229</a>
</td>
<td style="text-align:center;">
In this study, the bioactivity of some selected heterocyclic drugs named Favipiravir (<b>1</b>), Amodiaquine (<b>2</b>), 2’-Fluoro-2’-deoxycytidine (<b>3</b>), and Ribavirin (<b>4</b>) was evaluated as inhibitors and nucleotide analogues for COVID-19 using computational modeling strategies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32503657" target="_blank">32503657</a>
</td>
<td style="text-align:center;">
We will enroll patients who are discharged after treatment, whose nucleic acid test has changed from negative to positive during the screening visit, regardless of the severity of the symptoms, to investigate the mechanism, clinical outcome and therapeutic efficacy with Favipiravir patients with Corona virus Disease 2019. […] Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase, it has been used for treatment of some life-threatening infections such as Ebola virus, Lassa virus and rabies. […] Favipiravir group (experimental): Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, Oral administration, the maximum number of days taken will be no more than 14 days plus routine treatment for COVID-19. […] Trial participants, investigators, care givers, outcome assessors, and date analysts are not blinded to group assignment. 210 patients are expected to be enrolled and allocated according to the ratio of 2 (Favipiravir group, n=140): 1(regular treatment group, n=70).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32514228" target="_blank">32514228</a>
</td>
<td style="text-align:center;">
Certain drugs that are clinically approved for other diseases were tested against COVID-19 as chloroquine, hydroxychloroquine, ivermectin, favipiravir, ribavirin, and remdesivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32526208" target="_blank">32526208</a>
</td>
<td style="text-align:center;">
Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this despite an incomplete mechanistic understanding of the viral RNA-dependent RNA polymerase nsp12 drug interactions.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32532939" target="_blank">32532939</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32536670" target="_blank">32536670</a>
</td>
<td style="text-align:center;">
In light of the recent pandemic, favipiravir (Avigan<sup>®</sup>), a purine nucleic acid analog and antiviral agent approved for use in influenza in Japan, is being studied for the treatment of coronavirus disease 2019 (COVID-19). […] Increase in blood uric acid level is a frequent side effect of favipiravir. […] Here, we discussed the mechanism of blood uric acid elevation during favipiravir treatment. […] Favipiravir is metabolized to an inactive metabolite M1 by aldehyde oxidase and xanthine oxidase, and excreted into urine. […] Favipiravir and M1 act as moderate inhibitors of organic anion transporter 1 and 3 (OAT1 and OAT3), which are involved in uric acid excretion in the kidney. […] Thus, favipiravir is thought to decrease uric acid excretion into urine, resulting in elevation of uric acid levels in blood. […] Elevated uric acid levels were returned to normal after discontinuation of favipiravir, and favipiravir is not used for long periods of time for the treatment of viral infection. […] Nevertheless, the adverse effect of favipiravir might be clinically important in patients with a history of gout, hyperuricemia, kidney function impairment (in which blood concentration of M1 increases), and where there is concomitant use of other drugs affecting blood uric acid elevation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32538209" target="_blank">32538209</a>
</td>
<td style="text-align:center;">
We encourage giving more attention to favipiravir, remdesivir, and measles vaccine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32554953" target="_blank">32554953</a>
</td>
<td style="text-align:center;">
Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32555446" target="_blank">32555446</a>
</td>
<td style="text-align:center;">
According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32556649" target="_blank">32556649</a>
</td>
<td style="text-align:center;">
Interferon beta-1b subcutaneous injection was initiated immediately to enhance anti-viral therapy, and favipiravir on ICU day 10 upon availability.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32561148" target="_blank">32561148</a>
</td>
<td style="text-align:center;">
Novel experimental therapies, such as remdesivir and favipiravir, are also actively being investigated for antiviral efficacy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32564306" target="_blank">32564306</a>
</td>
<td style="text-align:center;">
To the best of our knowledge, favipiravir and anti-cytokine treatments have not been previously reported in a kidney transplant recipient with SARS-CoV-2 infection before.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32572376" target="_blank">32572376</a>
</td>
<td style="text-align:center;">
Based on the previous experiences with similar coronavirus management and present preliminary data from uncontrolled studies, drugs like chloroquine, hydroxychloroquine, remdesivir, lopinavir/ritonavir, and favipiravir have been recommended by the researchers to manage COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32572842" target="_blank">32572842</a>
</td>
<td style="text-align:center;">
In particular, information has spread about some drugs approved for other indications (chloroquine, hydroxychloroquine, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, favipiravir, and umifenovir) that could have led to inappropriate and therefore hazardous use.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32573355" target="_blank">32573355</a>
</td>
<td style="text-align:center;">
In addition to the selected compounds, 4 nucleoside analogs of anti-viral (Raltgravir, Maraviroc and Favipiravir) and anti-inflammatory (Prednisolone) drugs were selected for further investigations.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32580215" target="_blank">32580215</a>
</td>
<td style="text-align:center;">
The patient was given NIMV (non-invasive mechanical ventilation), and hydroxychloroquine, favipiravir and azithromycin in isolation intensive care, with the diagnosis of severe pneumonia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32584236" target="_blank">32584236</a>
</td>
<td style="text-align:center;">
Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32585765" target="_blank">32585765</a>
</td>
<td style="text-align:center;">
Darunavir together with ritonavir, hydroxychloroquine, azithromycin, and favipiravir were initiated on the first day of admission at primary hospital.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/terms/">Terms</a>
    
    
        &middot; 
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
